Auspex Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Auspex Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013077
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Auspex Pharmaceuticals Inc (Auspex), a subsidiary of Teva Pharmaceutical Industries Ltd is a biopharmaceutical company that develops and commercializes novel medicines for the treatment of movement disorders and other rare diseases including orphan diseases. The company offers products for the unmet medical needs in hyperkinetic movement disorders such as Tardive Dyskinesia, chorea associated with Huntington’s disease, and Tourette syndrome, and other orphan indications. Auspex’s product candidate SD-809, is small molecule inhibitor of vesicular monoamine 2 transporter used for the treatment of chorea. Its SD-560 is used for the treatment of idiopathic pulmonary fibrosis. Auspex is headquartered in La Jolla, California, the US.

Auspex Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Auspex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Auspex Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Auspex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Auspex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Auspex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Auspex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Auspex Pharma Raises US$20 Million In Series E Financing 10
Auspex Pharma Raises US$25 Million In Series D Financing 12
Auspex Pharma Raises US$1.5 Million In Venture Financing 13
Licensing Agreements 14
Auspex Pharma Enters into Licensing Agreement with Imphar 14
Equity Offering 15
Auspex Pharma Raises USD203.4 Million in Public Offering of Shares 15
Auspex Pharma Raises USD69.7 Million in Public Offering of Shares 17
Auspex Pharma Completes IPO For US$96.6 Million 19
Acquisition 21
Auspex Pharma Acquires Imphar 21
Teva Pharma Acquires Auspex Pharma 22
Auspex Pharmaceuticals Inc – Key Competitors 24
Auspex Pharmaceuticals Inc – Key Employees 25
Auspex Pharmaceuticals Inc – Locations And Subsidiaries 26
Head Office 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Auspex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Auspex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Auspex Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Auspex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Auspex Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Auspex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Auspex Pharma Raises US$20 Million In Series E Financing 10
Auspex Pharma Raises US$25 Million In Series D Financing 12
Auspex Pharma Raises US$1.5 Million In Venture Financing 13
Auspex Pharma Enters into Licensing Agreement with Imphar 14
Auspex Pharma Raises USD203.4 Million in Public Offering of Shares 15
Auspex Pharma Raises USD69.7 Million in Public Offering of Shares 17
Auspex Pharma Completes IPO For US$96.6 Million 19
Auspex Pharma Acquires Imphar 21
Teva Pharma Acquires Auspex Pharma 22
Auspex Pharmaceuticals Inc, Key Competitors 24
Auspex Pharmaceuticals Inc, Key Employees 25

★海外企業調査レポート[Auspex Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • China Investment Corp:企業のM&A・事業提携・投資動向
    China Investment Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China Investment Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Asklepios BioPharmaceutical Inc-製薬・医療分野:企業M&A・提携分析
    Summary Asklepios Biopharmaceutical Inc (AskBio) is a biotechnology company that develops and markets novel protein and cellular based therapies. The company has developed library of rAAV biological nano particles that provides unsurpassed transduction. Its products include such as biostrophin, AskB …
  • Coolgardie Minerals Ltd (CM1):企業の財務・戦略的SWOT分析
    Coolgardie Minerals Ltd (CM1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • DocCheck AG (AJ91):企業の財務・戦略的SWOT分析
    DocCheck AG (AJ91) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Brain Tunnelgenix Technologies Corp:医療機器:M&Aディール及び事業提携情報
    Summary Brain Tunnelgenix Technologies Corp (BTT Corp) is a medtech company that develops, manufactures and markets solutions based on the brain thermal tunnel. The company offers various research system, windows based application which provides the sensor data acquisition, data ingestion up to the …
  • NXT Energy Solutions Inc (SFD):企業の財務・戦略的SWOT分析
    Summary NXT Energy Solutions Inc (NXT Energy), formerly Energy Exploration Technologies Inc is an oilfield service company that offers geophysical services to the upstream oil and gas industry. The company provides Stress Field Detection (SFD) a patent pending gravity-based instrument that provides …
  • Mitsubishi Gas Chemical Co Inc (4182):製薬・医療:M&Aディール及び事業提携情報
    Summary Mitsubishi Gas Chemical Co Inc (MGC) is a chemicals company. It provides various products in a wide range of fields from basic chemicals to fine chemicals and functional materials. The company produces and sells xylene isomers, xylene derivatives and foaming plastics; inorganic chemicals and …
  • Koch Enterprises, Inc.:企業の戦略・SWOT・財務情報
    Koch Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report Summary Koch Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Kayne Anderson Capital Advisors LP:企業のM&A・事業提携・投資動向
    Kayne Anderson Capital Advisors LP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Kayne Anderson Capital Advisors LP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on m …
  • University of Southampton-製薬・医療分野:企業M&A・提携分析
    Summary University of Southampton (UOS) is an educational institute that offers undergraduate and postgraduate programs. The university offers educational programs across various disciplines including accounting and finance, acoustical engineering, aeronautics and astronautics, anthropology, archaeo …
  • DH Private Equity Partners:企業の戦略・SWOT・財務情報
    DH Private Equity Partners - Strategy, SWOT and Corporate Finance Report Summary DH Private Equity Partners - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Principia Biopharma Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Principia Biopharma Inc (Principia Biopharma) is a clinical stage biopharmaceutical company that designs and develops oral small molecule drug therapies. The company’s proprietary Tailored Covalency technology helps to develop portfolio of drugs such as Bruton's tyrosine kinase inhibitor. It …
  • CytRx Corp (CYTR):製薬・医療:M&Aディール及び事業提携情報
    Summary CytRx Corp (CytRx) is a clinical state is a biopharmaceutical company focusing on the research and development of novel treatments for cancer. The company’s oncology based product comprises of its lead drug product candidate, aldoxorubicin (formerly INNO-206). Aldoxorubicin is a pro-drug of …
  • Bausch & Lomb Inc:医療機器:M&Aディール及び事業提携情報
    Summary Bausch & Lomb Inc (Bausch & Lomb), a subsidiary of Valeant Pharmaceuticals International Inc, is a vision-care company with focus on the protection, enhancement and restoration of eyesight. It offers over-the-counter supplements, eye care products, contact lenses, ophthalmic pharmaceuticals, …
  • Eisai Co., Ltd.:企業のM&A・事業提携・投資動向
    Eisai Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Eisai Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Senvion SA:企業の戦略的SWOT分析
    Senvion SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Nuclear Power Corporation of India Ltd:企業の戦略的SWOT分析
    Nuclear Power Corporation of India Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • Fog Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Fog Pharmaceuticals Inc (Fog Pharmaceuticals) is a clinical-stage biotechnology company that discovers and develops next-generation peptide inhibitors that target traditionally undruggable intracellular protein-protein interactions. The company develops cell-penetrating miniproteins (CPMPs), …
  • Chembio Diagnostic Inc (CEMI):企業の財務・戦略的SWOT分析
    Chembio Diagnostic Inc (CEMI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • U.S. Energy Corp (USEG):石油・ガス:M&Aディール及び事業提携情報
    Summary U.S. Energy Corp (US Energy) is an oil and gas company that offers exploration, development and production of oil and natural gas properties. The company provides maintenance of mineral properties. It operates its oil and gas prospects located in the Williston Basin of North Dakota, the Eagl …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆